ATE273704T1 - Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung - Google Patents

Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung

Info

Publication number
ATE273704T1
ATE273704T1 AT00939556T AT00939556T ATE273704T1 AT E273704 T1 ATE273704 T1 AT E273704T1 AT 00939556 T AT00939556 T AT 00939556T AT 00939556 T AT00939556 T AT 00939556T AT E273704 T1 ATE273704 T1 AT E273704T1
Authority
AT
Austria
Prior art keywords
ophthalmic
histamine
containing compositions
concentration
pharmaceutically acceptable
Prior art date
Application number
AT00939556T
Other languages
English (en)
Inventor
Kurt R Gehlsen
Original Assignee
Maxim Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc
Application granted granted Critical
Publication of ATE273704T1 publication Critical patent/ATE273704T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00939556T 1999-06-03 2000-06-02 Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung ATE273704T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13756499P 1999-06-03 1999-06-03
PCT/US2000/015379 WO2000074649A2 (en) 1999-06-03 2000-06-02 Ophthalmic histamine compositions and uses thereof

Publications (1)

Publication Number Publication Date
ATE273704T1 true ATE273704T1 (de) 2004-09-15

Family

ID=22478011

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00939556T ATE273704T1 (de) 1999-06-03 2000-06-02 Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung

Country Status (11)

Country Link
US (1) US6531120B2 (de)
EP (1) EP1187611B1 (de)
AT (1) ATE273704T1 (de)
AU (1) AU777655B2 (de)
CA (1) CA2376108A1 (de)
DE (1) DE60013126T2 (de)
DK (1) DK1187611T3 (de)
ES (1) ES2225156T3 (de)
HK (1) HK1045458B (de)
PT (1) PT1187611E (de)
WO (1) WO2000074649A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012084B2 (en) 2001-02-28 2006-03-14 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US7115628B2 (en) 2001-07-18 2006-10-03 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
WO2003082081A2 (en) * 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
WO2004024720A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
DE10312140B4 (de) * 2003-03-19 2006-10-05 Johnson Controls Gmbh Feststell- und Neigungsverstellvorrichtung für Beschläge
US20040248959A1 (en) * 2003-04-30 2004-12-09 Bender Scott C. Histamine containing eye drops for visual identification of lymphoid tissue within the tissues of the eye, that are to be samples for further diagnostic testing
JP4834829B2 (ja) * 2005-03-31 2011-12-14 国立大学法人山口大学 クラミジア属細菌の抑制に効果のあるトリプトファン代謝中間産物
WO2010020052A1 (en) * 2008-08-21 2010-02-25 Edouard Kouassi Methods and compounds for increasing red blood cell survival
RU2411926C2 (ru) * 2009-01-13 2011-02-20 Надежда Витальевна Корсакова Способ консервативного лечения и профилактики ядерного вида возрастной катаракты
RU2418568C2 (ru) * 2009-04-20 2011-05-20 Надежда Витальевна Корсакова Способ консервативного лечения и профилактики коркового вида возрастной катаракты
CN104337760B (zh) * 2013-08-02 2018-09-04 山东新时代药业有限公司 一种二盐酸组胺注射液及其制备方法
CN110075063A (zh) * 2019-05-27 2019-08-02 合肥亿帆生物医药有限公司 一种二盐酸组胺注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510145A (en) * 1980-12-02 1985-04-09 Schachar Ronald A Method for inhibiting contraction of ophthalmic wounds or incisions
US5679337A (en) * 1991-06-14 1997-10-21 Professional Pharmaceutical, Inc. Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient
IL101441A (en) 1992-04-01 1999-07-14 Univ Ramot Pharmaceutical preparations for the treatment and prevention of diseases or irregularities in the eye
HK1004520A1 (en) 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
US5401327A (en) 1993-06-18 1995-03-28 Wilmington Partners L.P. Method of treating contact lenses
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
CA2160779C (en) * 1994-03-02 2008-08-26 Bruce A. Jack Method and composition for topical treatment of damaged tissue using histamine phosphate as active ingredient
US5861148A (en) 1995-01-23 1999-01-19 Smith; Stewart Gregory Ophthalmic compositions and process of using
US5895645A (en) 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
AU2434297A (en) * 1996-05-23 1997-12-09 Alcon Laboratories, Inc. The use of 5-ht1b/1d agonists to treat ocular pain
AU4249297A (en) * 1996-10-31 1998-05-22 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors

Also Published As

Publication number Publication date
EP1187611B1 (de) 2004-08-18
PT1187611E (pt) 2004-10-29
DE60013126D1 (de) 2004-09-23
WO2000074649A3 (en) 2002-01-17
DK1187611T3 (da) 2004-10-11
CA2376108A1 (en) 2000-12-14
AU5462700A (en) 2000-12-28
HK1045458B (en) 2005-03-24
ES2225156T3 (es) 2005-03-16
AU777655B2 (en) 2004-10-28
DE60013126T2 (de) 2005-09-08
HK1045458A1 (en) 2002-11-29
US20020098224A1 (en) 2002-07-25
WO2000074649A2 (en) 2000-12-14
US6531120B2 (en) 2003-03-11
EP1187611A2 (de) 2002-03-20

Similar Documents

Publication Publication Date Title
ATE273704T1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
JO1605B1 (en) Derivatives 2- aminopyrimidone
TW355683B (en) Composition containing micronized nebivolol
AP1853A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents.
SE9504661D0 (sv) New compounds
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
ATE197401T1 (de) Chinazolinon-arzneimittel sowie deren verwendung
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
TR200102977T2 (tr) Yeni tedavi yöntemi.
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
NZ237309A (en) 1-(2-(4-morpholino)ethyl)-3-(arylcarbonyl)-indole derivatives and pharmaceutical compositions
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
ES2194055T3 (es) Nuevo uso de prostaglandinas.
IT1255802B (it) Derivati imidazolici ad attivita' a ii antagonista
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
NZ514558A (en) Viral treatment
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
ATE281464T1 (de) Adenosinderivate und deren verwendung
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
DE69713067D1 (de) Aminotetralinderivate, deren zusammensetzungen sowie deren verwendung
AU9157698A (en) Piperazine derivatives active on the lower urinary tract

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1187611

Country of ref document: EP

REN Ceased due to non-payment of the annual fee